Search

Your search keyword '"Furman, Richard"' showing total 582 results

Search Constraints

Start Over You searched for: Author "Furman, Richard" Remove constraint Author: "Furman, Richard" Language english Remove constraint Language: english
582 results on '"Furman, Richard"'

Search Results

2. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

4. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

7. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans

8. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

11. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

15. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

20. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

22. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

25. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL

26. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

27. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

28. Postibrutinib outcomes in patients with mantle cell lymphoma

33. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

34. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

36. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

38. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

39. Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

40. Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

42. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response

43. 'I Want Child Care He's Gonna Be Happy in': A Case Study of a Father's Child Care Experiences

44. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

45. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

48. Persistent and Relapsing Babesiosis in Immunocompromised Patients

50. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Catalog

Books, media, physical & digital resources